 | Fred D LublinCorinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA. | The Corinne Goldsmith Dickinson ... |
KOL Resume for Fred D Lublin (disease, demyelinating disease, sclerosis, demyelinating)
| Year | |
|---|---|
| 2022 | Corinne Dickinson Goldsmith Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 E 98th Street, New York, NY 10029, USA. |
| 2021 | Icahn School of Medicine at Mount Sinai, New York, NY; |
| 2020 | From the Department of Health Sciences (DISSAL) (F.B., M.P.S.), University of Genoa, Italy; CORe (T.K., C.M.), Department of Medicine, University of Melbourne, Australia; Department of Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology and Center for Clinical Neuroscience (D.H., E.K.H.), First Medical Faculty, Charles University, Prague, Czech Republic; Department of Basic Medical Sciences, Neuroscience and Sense Organs (M. Trojano), University of Bari, Italy; Department of Neuroscience (A.P., M.G., P.D.), Faculty of Medicine, Université de Montréal, Quebec, Canada; Department of Neuroscience, Imaging, and Clinical Sciences (M.O.), University G. d'Annunzio, Chieti; IRCCS Istituto delle Scienze Neurologiche di Bologna (A.L.); Dipartimento di Scienze Biomediche e Neuromotorie (A.L.), Università di Bologna, Italy; Hospital Universitario Virgen Macarena (G. Izquierdo. S.E.), Sevilla, Spain; Department of Medical, Surgical Science and Advanced Technology "GF Ingrassia" (F.P.), University of Catania, Italy; Ondokuz Mayis University (M. Terzi), Department of Neurology, Samsun, Turkey; CISSS Chaudi're-Appalache (P.G.), Centre-Hospitalier, Levis, Quebec, Canada; IRCCS Mondino Foundation (R.B.), Pavia; Department of Neuroscience (P.S., D.F.), Azienda Ospedaliera Universitaria, Modena, Italy; Department of Neurology (S.O.), Dokuz Eylul University, Izmir, Turkey; Ospedali Riuniti di Salerno (G. Iuliano), Salerno, Italy; Department of Neurology (C.B.), Karadeniz Technical University, Trabzon, Turkey; Department of Neurology (R.H.), Zuyderland Medical Center, Sittard, the Netherlands; Neuro Rive-Sud (F.G.), Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada; Clinico San Carlos (C.O.-G), Madrid, Spain; Cliniques Universitaires Saint-Luc (V.v.P.); Université Catholique de Louvain (V.v.P.), Brussels, Belgium; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; Kommunehospitalet (T.P.), Arhus C, Denmark; Koc University (A.A.), School of Medicine; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; Hospital Germans Trias i Pujol (C.R.-T.), Badalona, Spain; University of Queensland (P.M.), Brisbane, Australia; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Central Clinical School (H.B.), Monash University, Melbourne, Australia; The University of Texas Health Science Center at Houston (J.S.W.); Rehabilitation Unit (C.S.), "Mons. L. Novarese" Hospital, Moncrivello; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genoa, Italy. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| 2019 | From the Departments of Diagnostic and Interventional Imaging (P.A.N., I.C., S.J.S., R.E.G.) and Neurology (J.S.W.), McGovern Medical School, University of Texas Health Science Center, 6431 Fannin St, Houston, TX 77030; and Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574 (F.D.L.). Mount Sinai Medical Center, New York, NY, USA |
| 2018 | Icahn School of Medicine at Mount Sinai The Corinne Goldsmith Dickinson Center for Multiple Sclerosis New York New York Mount Sinai Medical Center |
| 2017 | Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, United States Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA, . Icahn School of Medicine at Mount Sinai, NY, US |
| 2016 | Icahn School of Medicine at Mount Sinai, New York City, NY, USA Department of Neurology, Mount Sinai Hospital, New York, New York, United States of America |
| 2015 | Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY USA Icahn School of Medicine at Mount Sinai, New York, NY 10029; email: , , |
| 2014 | Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for MS, 5 E. 98th Street, Box 113B, New York, NY, USA |
| 2013 | Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Friedman Brain Institute, Mount Sinai School of Medicine, 5 East 98th Street, Box 1138, New York, NY 10029, USA |
| 2012 | Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, 5 E 98th St #1138, 10029, New York, NY, USA Professor and Chair Emeritus of Neurology, School of Medicine, Case Western Reserve University, Cleveland, Ohio Chair, Department of Neurology; Pierson-Lovelace Investigator; Stark Chair in Neurology; Director, Brain Mapping Center; Associate Director, Semel Institute, David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, California |
| 2011 | Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Mount Sinai Medical Center, 5 East 98th Street, Box 1138, New York, NY 10029, USA Corrine Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Mount Sinai School of Medicine, New York, NY |
| 2010 | Department of Neurology, Mount Sinai School of Medicine, New York, NY |
| 2009 | From the University of Rochester Medical Center (A.D.G.), Rochester, NY; Michigan Institute for Neurological Disorders (H.R.), Farmington Hills, MI; Montreal Neurological Institute (A.B.-O.), Montreal, Quebec, Canada; Mount Sinai School of Medicine (A.M., F.L.), New York, NY; Institute of Neurology (D.H.M., K.S.), University College London, UK; Wayne State University School of Medicine (O.K.), Detroit, MI; and Biogen Idec, Inc. (N.M.B., M.Y., M.A.P., A.W.S.), Cambridge, MA. Dept. of Neurology, Stony Brook University Medical Center, HSC T12–020, Stony Brook, NY, 11794–8121 Mount Sinai Medical Center Department of Neurology, New York, NY, USA |
| 2008 | Professor of Neurology From the Medical University of Graz (F.F.), Austria; The Mount Sinai School of Medicine (F.D.L.), New York, NY; University of British Columbia and UBC Hospital (D.L.), Vancouver, Canada; The Ottawa Hospital–General Campus (M.S.F.), Ottawa, Canada; Heinrich-Heine-Universität (H.P.H.), Düsseldorf, Germany; Neurologische Universitätsklinik (P.R.), Würzburg, Germany; Copenhagen University Hospital Rigshospitalet (P.S.S.), Copenhagen, Denmark; Bayer HealthCare AG (M.M.-E.), Leverkusen, Germany; Bayer Vital GmbH (B.S.), Leverkusen, Germany; and Talecris Biotherapeutics (K.H.), Research Triangle Park, NC. Corrine Goldsmith Dickinson Center for Multiple Sclerosis, Mt. Sinai School of Medicine, New York City, New York, USA Neurologist-in-Chief, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee |
| 2007 | From the Johns Hopkins Multiple Sclerosis Center (P.A.C.), Baltimore, MD; Institute of Neurology (G.G., D.H.M.), London, UK; Hôpital Neurologique (C.C.), Lyon, France; University of Pennsylvania School of Medicine (S.L.G.), Philadelphia; Neurological Department (E.H.), General Teaching Hospital, Prague, Czech Republic; St Vincent's University Hospital (M.H.), Dublin, Ireland; University Hospitals Basel (L.K., E.-W.R.), Switzerland; St. Michael's Hospital (P.W.O'C.), Toronto, Ontario, Canada; Texas Neurology (J.T.P.), Dallas; VU Medical Centre (C.H.P.), Amsterdam, the Netherlands; Mellon Center for Multiple Sclerosis Treatment and Research (R.A.R.), Cleveland Clinic Foundation, OH; MS Center of Atlanta (W.H.S.), GA; Mt. Sinai School of Medicine (F.D.L.), New York; Silesian Medical University (A.W.), Katowice, Poland; Jacobs Neurological Institute (B.W.-G.), SUNY University at Buffalo, NY; Consultants in Neurology Multiple Sclerosis Center (D.R.W.), Northbrook, IL; and Biogen Idec, Inc. (F.L., M.A.P.), Cambridge, MA. Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, 5 East 98th Street, Box 1138, New York, New York 10029, USA Department of Neurology, Mt. Sinai School of Medicine, New York, NY |
| 2006 | Department of Neurology, Mount Sinai School of Medicine, New York, NY (Dr Lublin) From the Multiple Sclerosis Center at Texas Neurology (J.T.P.), Dallas, TX; St. Michael’s Hospital (P.W.O.), Toronto, Ontario, Canada; General Teaching Hospital (E.H.), Prague, Czech Republic; St. Vincent’s University Hospital (M.H.), Dublin, Ireland; University Hospitals Basel (L.K.), Basel, Switzerland; Institute of Neurology (D.H.M., G.G.), London, UK; VU Medical Centre (C.H.P.), Amsterdam, The Netherlands; Mt. Sinai School of Medicine (F.D.L.), New York, NY; Silesian Medical University (A.W.), Katowice, Poland; and Biogen Idec, Inc. (F.L., M.A.P., A.W.S.), Cambridge, MA. Mt. Sinai School of Medicine, New York (F.D.L.) |
Prominent publications by Fred D Lublin
BACKGROUND: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients.
METHODS: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive ...
| Known for Patients Placebo | Multiple Sclerosis | 3 Trial | Fingolimod Disability Progression | Relapsing Remitting |
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
[ PUBLICATION ]
BACKGROUND: No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis.
METHODS: In INFORMS, a multicentre, double-blind, placebo-controlled parallel-group study, patients with primary ...
| Known for Patients Fingolimod | Primary Progressive | Multiple Sclerosis | Placebo 1 | 2 Years |
BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.
METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse ...
| Known for Multiple Sclerosis | Ocrelizumab Interferon | Humanized Antigens | P0001 Trial | Disability Progression |
BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.
METHODS: In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 ...
| Known for Ocrelizumab Placebo | Multiple Sclerosis | Percentage Patients | Humanized Antigens | Primary Progressive |
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
[ PUBLICATION ]
BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis.
METHODS: Of a total of 942 patients, 627 were randomly assigned to receive natalizumab (at a dose of 300 mg) and 315 to receive placebo by intravenous infusion every four weeks for more than two years. The primary end points were the rate of clinical relapse ...
| Known for Relapsing Multiple | Natalizumab Placebo | Clinical Relapse | Sustained Progression | Monoclonal Antibodies |
BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies.
METHODS: We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon ...
| Known for Multiple Sclerosis | Interferon Beta | Combination Therapy | Monoclonal Antibodies | Cumulative Probability |
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
[ PUBLICATION ]
The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with relapsing multiple sclerosis (MS). Further analyses of AFFIRM and SENTINEL data were conducted to determine the efficacy of natalizumab in prespecified patient subgroups according to baseline characteristics: relapse history 1 year before randomization (1, 2, ≥ 3), Expanded Disability Status Scale score (≤ 3.5, > 3.5), number of T2 ...
| Known for Natalizumab Patients | Multiple Sclerosis | Monoclonal Antibodies | Subgroup Analyses | Highly Active Disease |
BACKGROUND: No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.
METHODS: We did a multicentre, double-blind, randomised placebo-controlled phase 2/3 study at 99 outpatient specialty clinics or hospitals in ...
| Known for Placebo Inebilizumab | Neuromyelitis Optica | Nmosd Attack | Spectrum Disorder | 174 Participants |
OBJECTIVE: To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab.
METHODS: In two randomized, double-blind, placebo-controlled studies (natalizumab safety and efficacy in relapsing remitting multiple sclerosis [MS, AFFIRM] and safety and efficacy of natalizumab in combination with interferon beta-1a [INF beta]1a] in patients with relapsing remitting MS [SENTINEL]) of patients with relapsing multiple sclerosis, blood samples were ...
| Known for Natalizumab Antibodies | Patients Multiple Sclerosis | Persistently Positive | Relapsing Remitting | Blood Samples |
BACKGROUND: The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity.
METHODS: Post-hoc analyses of data from the AFFIRM study were done to determine the effects of natalizumab compared with placebo on the ...
| Known for Multiple Sclerosis | Monoclonal Antibodies | Retrospective Analysis | Natalizumab Safety | Radiological Disease |
OBJECTIVE: To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab.
METHODS: HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300 mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in ...
| Known for Multiple Sclerosis | Monoclonal Antibodies | Patients Natalizumab | Health‐related Quality | Baseline Week |
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
[ PUBLICATION ]
Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the treatment of relapsing MS. We evaluated the effects of teriflunomide treatment on relapse-related neurological sequelae and healthcare resource use in a post hoc analysis of the Phase III TEMSO study. Confirmed relapses associated with neurological sequelae [defined by an increase in Expanded Disability Status Scale/Functional System ...
| Known for Teriflunomide Treatment | Multiple Sclerosis Relapses | Annualized Rates | Sequelae Investigator | Hospitalization Relapse |
BACKGROUND: In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with relapsing multiple sclerosis (MS), natalizumab significantly reduced the relapse rate by 68% and progression of sustained disability by 42% vs placebo. We report the effect of natalizumab on MRI measures from the AFFIRM study.
METHODS: The number and volume of gadolinium (Gd)-enhancing, new or enlarging ...
| Known for Mri Outcomes | Multiple Sclerosis Natalizumab | Monoclonal Antibodies | 2 Years | Controlled Trial |
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated ...
| Known for Multiple Sclerosis | 2017 Revisions | Mcdonald Criteria | Dissemination Space | Time Patients |
OBJECTIVE: To examine the effects of natalizumab on low-contrast letter acuity as a prespecified tertiary endpoint in two randomized clinical trials and to evaluate the usefulness of low-contrast letter acuity testing as a candidate test of visual function in multiple sclerosis (MS).
METHODS: AFFIRM and SENTINEL were randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trials of natalizumab in relapsing MS. Natalizumab was evaluated as monotherapy in AFFIRM and as ...
| Known for Multiple Sclerosis | Visual Loss | Monoclonal Antibodies | Contrast Acuity | Hazard Ratio |
Fred D Lublin: Influence Statistics
| Concept | World rank |
|---|---|
| genetic analysis autoimmune | #1 |
| cytotoxic myelin proteins | #1 |
| virus mhv4 | #1 |
| cortical lesion ppms | #1 |
| clinical disease b10s | #1 |
| demyelinating disease findings | #1 |
| jc virus development | #1 |
| ifnbeta1a monoclonal antibodies | #1 |
| repeated mri studies | #1 |
| cvlt cerebellar volumes | #1 |
| inflammatory demyelination lymphocytes | #1 |
| remitting rrms patients | #1 |
| chs siblings | #1 |
| gcipl thinning cls | #1 |
| scans 12 regions | #1 |
| eaesusceptible sjl mice | #1 |
| inflammatory demyelination studies | #1 |
| fingolimod nadir | #1 |
| lcva 125 | #1 |
| 1 cis definition | #1 |
| pattern reae | #1 |
| mhv4 uvmhv4 exposure | #1 |
| balb endothelial cells | #1 |
| lublinreingold criteria | #1 |
| rrms association | #1 |
| awf cst | #1 |
| awf ptr | #1 |
| betweenrater concordance | #1 |
| baseline awf cst | #1 |
| diffusivity corticospinal tracts | #1 |
| cellmediated disorder | #1 |
| neda dti | #1 |
| cognitive multitasking early | #1 |
| neda criteria | #1 |
| substantial il6 response | #1 |
| 7t mri protocol | #1 |
| neurometabolic disorders recognition | #1 |
| t25fw improvement patients | #1 |
| field hypothesis activity | #1 |
| dmsws12 questionnaire | #1 |
| views nosologic relations | #1 |
| large coalescent lesions | #1 |
| eae cns tissue | #1 |
| sjl msch preparations | #1 |
| detection cellular responses | #1 |
| tracts timed | #1 |
| findings identical | #1 |
| inflammatory cell entry | #1 |
| ppms awf | #1 |
| target rrms | #1 |
Open the FULL List in Excel | |
Key People For Multiple Sclerosis
Fred D Lublin:Expert Impact
Concepts for whichFred D Lublinhas direct influence:Multiple sclerosis, Glatiramer acetate, Sleep disturbance, Patients multiple sclerosis, Monoclonal antibodies, Endothelial cells, Immune tolerance, Natalizumab antibodies.
Fred D Lublin:KOL impact
Concepts related to the work of other authors for whichfor which Fred D Lublin has influence:Multiple sclerosis, Neuromyelitis optica, Central nervous, Magnetic resonance, Cognitive impairment, Spinal cord, Relapsing remitting.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |